Paolo De Martini

Dr. Paolo De Martini

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2010 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
RPRaffaele Pugliese
Raffaele Pugliese
DMDario Maggioni
Dario Maggioni
FSFabio Sansonna
Fabio Sansonna
ACAndrea Costanzi
Andrea Costanzi
GFGiovanni Carlo Ferrari
Giovanni Carlo Ferrari
FPFrancesco Pugliese
Francesco Pugliese

9 February 2013 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
CMCarmelo Magistro
Carmelo Magistro
SLStefano Di Lernia
Stefano Di Lernia
GFGiovanni Ferrari
Giovanni Ferrari
AZAntonio Zullino
Antonio Zullino
MMMichele Mazzola
Michele Mazzola
RPRaffaele Pugliese
Raffaele Pugliese

1 December 2017 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
PAPietro Achilli
Pietro Achilli
PMPaolo De Martini
Paolo De Martini
MCMarco Ceresoli
Marco Ceresoli
GMGiulio M. Mari
Giulio M. Mari
ACAndrea Costanzi
Andrea Costanzi
GFGiovanni Ferrari
Giovanni Ferrari
Background: To verify the prognostic value of the pathologic and radiological tumor response after neoadjuvant chemotherapy in the treatment of locally advanced gastric adenocarcinoma. Methods: A total of 67 patients with locally advanced gastric cancer (clinical ≥ T2 or nodal disease and without evidence of distant metastases) underwent perioperative chemotherapy (ECF or ECX regimen) from December 2009 through June 2015 in two surgical units. Histopathological and radiological response to chemotherapy were evaluated by using tumor regression grade (TRG) (Becker’s criteria) and volume change assessed by CT. Results: Fifty-one (86%) patients completed all chemotherapy scheduled cycles successfully and surgery was curative (R0) in 64 (97%) subjects. The histopathological analysis showed 19 (29%) specimens with TRG1 (less than 10% of vital tumor left) and 25 (37%) patients had partial or complete response (CR) assessed by CT scan. Median disease free survival (DFS) and overall survival (OS) were 25.70 months (range, 14.52–36.80 months) and 36.60 months (range, 24.3–52.9 months), respectively. The median follow up was 27 months (range, 5.00–68.00 months). Radiological response and TRG were found to be a prognostic factor for OS and DFS, while tumor histology was not significantly related to survival. Conclusions: Both radiological response and TRG have been shown as promising survival markers in patients treated with perioperative chemotherapy for locally advanced gastric cancer. Other predictive markers of response to chemotherapy are strongly required.

1 March 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MMMichele Mazzola
Michele Mazzola
AGAlessandro Giani
Alessandro Giani
JCJacopo Crippa
Jacopo Crippa
LMLorenzo Morini
Lorenzo Morini
AZAndrea Zironda
Andrea Zironda
GFGiovanni Ferrari
Giovanni Ferrari

26 January 2021 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PLPietro Maria Lombardi
Pietro Maria Lombardi
MMMichele Mazzola
Michele Mazzola
PAPietro Achilli
Pietro Achilli
MAMaria Costanza Aquilano
Maria Costanza Aquilano
PMPaolo De Martini
Paolo De Martini
GFGiovanni Ferrari
Giovanni Ferrari

25 August 2021 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
UBUmberto Bracale
Umberto Bracale
FCFrancesco Corcione
Francesco Corcione
GPGiusto Pignata
Giusto Pignata
JAJacopo Andreuccetti
Jacopo Andreuccetti
PDPasquale Dolce
Pasquale Dolce
RPRoberto Peltrini
Roberto Peltrini
Background and Objectives: In the setting of a minimally invasive approach, we aimed to compare short and long‐term postoperative outcomes of patients treated with neoadjuvant therapy (NAT) + surgery or upfront surgery in Western population.Methods: All consecutive patients from six Italian and one Serbian center with locally advanced gastric cancer who had undergone laparoscopic gastrectomy with D2 lymph node dissection were selected between 2005 and 2019. After propensity score‐matching, postoperative morbidity and oncologic outcomes were investigated.Results: After matching, 97 patients were allocated in each cohort with a mean age of 69.4 and 70.5 years. The two groups showed no difference in operative details except for a higher conversion rate in the NAT group (p = 0.038). The overall postoperative complications rate significantly differed between NAT + surgery (38.1%) and US (21.6%) group (p = 0.019). NAT was found to be related to a higher risk of postoperative morbidity in patients older than 60 years old (p = 0.013) but not in patients younger (p = 0.620). Conversely, no difference in overall survival (p = 0.41) and disease‐free‐survival (p = 0.34) was found between groups.Conclusions: NAT appears to be related to a higher postoperative complication rate and equivalent oncological outcomes when compared with surgery alone. However, poor short‐term outcomes are more evident in patients over 60 years old receiving NAT.